Skip to main content
Menu

Posts tagged with "Drug Industry History"

  • Chemical News

    Rings of the Future!

    Here’s an interesting paper that some of you may have seen in J. Med. Chem.: “Heteroaromatic Rings of the Future”. That’s an odd title, but an appropriate one. For the non-chemists in the crowd who made it to this paragraph, heteroaromatic rings are a very wide class of organic compounds. They’re flat cyclic structures… Read More
  • Cancer

    Thalidomide for Myeloma: Whose Idea Was It?

    So, if you’re a patient with a rare disease (or a relative of a patient with one), and you have an idea for repurposing an old drug for treatment. . .and you get a company interested, and it actually works. . .works to the point that the company takes in a billion or two dollars… Read More
  • Business and Markets

    Drug Companies Are Polar Bears? Maybe Not.

    There’s an interesting article up over at InVivoBlog, and I wanted to see what the readership here thought of its main premise. Subtracting out the cute ecological analogies (Big Pharma as polar bears, for example), you get to this: . . .For example, AstraZeneca, Novartis, and Bristol-Myers, all operate in the fields of neuroscience, oncology… Read More
  • Drug Development

    Spray-Painted For Success

    I do a lot of talking around here about how the general public doesn’t really have a good idea of what goes on inside a drug company. But a conversation with a colleague has put me to thinking that this might be largely our own fault. Consider the public face that our industry projects. Look… Read More
  • Business and Markets

    Pharma’s Return on Investment: Yikes

    There’s a recent article in Nature Reviews Drug Discovery that has some alarming figures in it. This is yet another look at the industry from McKinsey, and we’ll get to their McKinseyish solutions in a moment. But first, some numbers: They calculate that the return on investment (ROI) from small-molecule drug research was nearly 12% Read More
  • Academia (vs. Industry)

    Where Drugs Come From, and How. Once More, With A Roll of the Eyes

    I linked yesterday to a post by Megan McArdle about health care reform. And while I realize that everyone got into a shouting match in the comments to my own post on the subject – and people sure did in the comments to hers; it’s endemic – I wanted to quote a section from her… Read More
  • Alzheimer's Disease

    Amyloid in Trouble

    Here’s an interesting look at the current state of the Alzheimer’s field from Bloomberg. The current big hope is Wyeth (and Elan)’s bapineuzumab, which I last wrote about here. That was after the companies reported what had to be considered less-than-hoped-for efficacy in the clinic. The current trial is the one sorted out by APOE… Read More
  • Business and Markets

    Drug Approvals, Natural And Unnatural

    I seem to have been putting a lot of graphics up this week, so here’s another one. This is borrowed from a recent Science paper on the future of natural-products based drug discovery. It’s interesting both from that viewpoint, and because of the general approval numbers: And there you have it. Outside of anomalies like… Read More
  • Drug Assays

    Why Does Screening Work At All? (Free Business Proposal Included!)

    I’ve been meaning to get around to a very interesting paper from the Shoichet group that came out a month or so ago in Nature Chemical Biology. Today’s the day! It examines the content of screening libraries and compares them to what natural products generally look like, and they turn up some surprising things along… Read More
  • Business and Markets

    How Much Does the Drug Industry Spend on Marketing?

    Anyone who defends the pharmaceutical industry has to be ready to hear, over and over and over, about how much it spends on sales and marketing versus R&D. This is thought to be a telling point about where the priorities really are. I’ve addressed this one several times, and my best response is to point… Read More
...303132...